AR074507A1 - Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra. - Google Patents

Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra.

Info

Publication number
AR074507A1
AR074507A1 ARP090104739A ARP090104739A AR074507A1 AR 074507 A1 AR074507 A1 AR 074507A1 AR P090104739 A ARP090104739 A AR P090104739A AR P090104739 A ARP090104739 A AR P090104739A AR 074507 A1 AR074507 A1 AR 074507A1
Authority
AR
Argentina
Prior art keywords
crystalline form
nalmephene
dihydrated
chlorhydrate
alcoholism
Prior art date
Application number
ARP090104739A
Other languages
English (en)
Spanish (es)
Original Assignee
Lundbeck & Co As H
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074507(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H, Biotie Therapies Corp filed Critical Lundbeck & Co As H
Publication of AR074507A1 publication Critical patent/AR074507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
ARP090104739A 2008-12-05 2009-12-07 Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra. AR074507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200801729 2008-12-05

Publications (1)

Publication Number Publication Date
AR074507A1 true AR074507A1 (es) 2011-01-19

Family

ID=41571731

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104739A AR074507A1 (es) 2008-12-05 2009-12-07 Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra.

Country Status (30)

Country Link
US (2) US8530495B2 (enExample)
EP (2) EP2300479B1 (enExample)
JP (3) JP6055183B2 (enExample)
KR (2) KR20110089333A (enExample)
CN (2) CN104211707B (enExample)
AR (1) AR074507A1 (enExample)
AT (1) ATE546453T1 (enExample)
AU (1) AU2009321898B2 (enExample)
BR (1) BRPI0922774B8 (enExample)
CA (1) CA2744932C (enExample)
CL (1) CL2011001331A1 (enExample)
CO (1) CO6362012A2 (enExample)
CY (2) CY1112643T1 (enExample)
DK (2) DK2441766T3 (enExample)
EA (1) EA018948B1 (enExample)
ES (2) ES2380297T3 (enExample)
HR (2) HRP20120247T1 (enExample)
IL (1) IL213112A (enExample)
MX (1) MX2011005865A (enExample)
MY (1) MY149028A (enExample)
NZ (1) NZ593874A (enExample)
PL (2) PL2441766T3 (enExample)
PT (2) PT2300479E (enExample)
RS (2) RS52255B (enExample)
SG (1) SG171910A1 (enExample)
SI (2) SI2441766T1 (enExample)
SM (2) SMT201200014B (enExample)
TW (1) TWI465450B (enExample)
UA (1) UA102128C2 (enExample)
WO (1) WO2010063292A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
JP2019031524A (ja) * 2008-12-05 2019-02-28 ハー・ルンドベック・アクチエゼルスカベット ナルメフェン塩酸塩二水和物
TWI560170B (en) 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
WO2013164383A1 (en) 2012-05-03 2013-11-07 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005217A1 (en) * 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6479766B2 (ja) * 2013-04-17 2019-03-06 ハー・ルンドベック・アクチエゼルスカベット 不安障害患者の治療のためのナルメフェン
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
AR096851A1 (es) 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
MX2016013889A (es) 2014-04-22 2017-03-09 Otsuka Pharma Co Ltd Medicamento.
TWI681954B (zh) 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
CN105646508B (zh) * 2016-02-17 2018-02-27 南京卓康医药科技有限公司 一种盐酸纳美芬一水合物的制备方法
WO2019022274A1 (ko) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN113354652A (zh) * 2021-06-24 2021-09-07 无锡济煜山禾药业股份有限公司 一种盐酸纳美芬合成方法
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CH693586A8 (de) * 2002-10-14 2003-12-15 Roche Consumer Health Ag Darreichungsform von Ibuprofen-Natrium.
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
PL1708690T3 (pl) * 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
MY139797A (en) * 2004-11-29 2009-10-30 Kowa Co (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate
CN100536848C (zh) * 2005-07-13 2009-09-09 北京易明康元医药科技有限公司 稳定的盐酸纳美芬注射液及其制备方法
GB2447016A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
AU2008223328B2 (en) * 2007-03-06 2012-10-11 SpecGx LLC Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
WO2008127618A1 (en) * 2007-04-12 2008-10-23 Mallinckrodt Inc. Crystalline and amorphous forms of naltrexone hydrochloride
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Also Published As

Publication number Publication date
TW201022273A (en) 2010-06-16
MY149028A (en) 2013-06-28
US8530495B2 (en) 2013-09-10
JP2012510954A (ja) 2012-05-17
PT2300479E (pt) 2012-04-10
CN104211707B (zh) 2017-04-12
JP2017025079A (ja) 2017-02-02
PL2300479T3 (pl) 2012-06-29
US8754217B2 (en) 2014-06-17
EP2300479A1 (en) 2011-03-30
EP2300479B1 (en) 2012-02-22
EA201170753A1 (ru) 2011-12-30
HRP20140648T1 (hr) 2014-09-26
ES2380297T3 (es) 2012-05-10
RS53415B (sr) 2014-12-31
CL2011001331A1 (es) 2011-08-26
CA2744932C (en) 2013-05-07
CN104211707A (zh) 2014-12-17
EA018948B1 (ru) 2013-11-29
PL2441766T3 (pl) 2014-09-30
PT2441766E (pt) 2014-08-05
JP6055183B2 (ja) 2016-12-27
IL213112A0 (en) 2011-07-31
TWI465450B (zh) 2014-12-21
NZ593874A (en) 2013-02-22
CN102325778A (zh) 2012-01-18
SI2441766T1 (sl) 2014-12-31
CO6362012A2 (es) 2012-01-20
IL213112A (en) 2013-06-27
AU2009321898A1 (en) 2011-07-14
BRPI0922774A2 (pt) 2017-07-11
SMT201400113B (it) 2014-11-10
CN102325778B (zh) 2014-08-13
SI2300479T1 (sl) 2012-07-31
RS52255B (sr) 2012-10-31
MX2011005865A (es) 2011-09-06
ATE546453T1 (de) 2012-03-15
UA102128C2 (en) 2013-06-10
US20130338365A1 (en) 2013-12-19
JP6591759B2 (ja) 2019-10-16
CY1115381T1 (el) 2017-01-04
DK2300479T3 (da) 2012-03-26
DK2441766T3 (da) 2014-07-21
CA2744932A1 (en) 2010-06-10
BRPI0922774B1 (pt) 2020-10-13
EP2441766B1 (en) 2014-06-25
HK1205108A1 (en) 2015-12-11
SMT201200014B (it) 2012-07-10
WO2010063292A1 (en) 2010-06-10
ES2488165T3 (es) 2014-08-26
KR20170008893A (ko) 2017-01-24
AU2009321898B2 (en) 2014-10-02
SG171910A1 (en) 2011-07-28
BRPI0922774B8 (pt) 2021-05-25
CY1112643T1 (el) 2016-02-10
KR20110089333A (ko) 2011-08-05
JP6591944B2 (ja) 2019-10-16
EP2441766A1 (en) 2012-04-18
HRP20120247T1 (hr) 2012-05-31
JP2015134785A (ja) 2015-07-27
US20110251228A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
AR074507A1 (es) Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra.
EA200802119A1 (ru) Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат
CA2875877C (en) Syk inhibitors
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
TN2012000248A1 (en) Novel spiropiperidine compounds
EA200601271A1 (ru) Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат
PH12015501813A1 (en) Monocyclic pyridine derivative
UA118550C2 (uk) Сіль абексиностату, пов'язана з нею кристалічна форма, спосіб її отримання й фармацевтичні композиції, що її містять
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
EA200601274A1 (ru) Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат
EA201270302A1 (ru) Безводные формы производных пиридина
CY1116086T1 (el) Ενυδρη υδροχλωρικη αγομελατινη και παρασκευη αυτης
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
AR076856A1 (es) Lenalidomida polimorfa y proceso para su preparacion
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
MY185971A (en) Pyranodipyridine compound
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2023004668A (es) Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico.
ES2489467T3 (es) Polimorfo novedoso del clorhidrato del éster (6-dimetilaminometil-2-naftalenílico) del ácido (4-hidroxicarbamoilfenil)-carbámico
MY152069A (en) Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation threof, and therepeutic use thereof
SG178880A1 (en) Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
AR107441A1 (es) Forma cristalina de cobicistat

Legal Events

Date Code Title Description
FB Suspension of granting procedure